BLOGS WEBSITE

Pfizer Pharmaceuticals: Global Research Awards for Nicotine Dependence (GRAND) 2015

The overall mission of the GRAND program is to advance the pharmacological treatment of tobacco and nicotine dependence.

Examples could include:

  • Observational or interventional studies of pharmacotherapy
  • Optimisation of the use of currently available medication
  • Effectiveness of treatment in real-life settings
  • Development or use of new medications for cessation or harm reduction
  • Specifically designed interventions in subtypes of tobacco/nicotine users
  • Use of existing databases to inform the clinical use of pharmacotherapy
  • Policy interventions to increase use of pharmacotherapy

Funding

Awards are funded at up to US $200,000 (approx. AUD $255,600) per project.

Eligibility

GRAND is open to all investigators from around the world holding an MD, a PhD, or equivalent.

Out-of-scope topics will not be funded, including:

  • Genetics
  • Epidemiology of tobacco use
  • Tobacco control policy not focused on pharmacotherapy

Submission Requirements

Applications must be submitted to the Research Branch for internal review by 24 June 2015.

Submitted applications must be accompanied by a signed and completed copy of the University’s Grant Application Cover Sheet. Submissions may be emailed to the Research Branch unless otherwise specified.

Grants Officer: Dr Don McMaster

Email: don.mcmaster@adelaide.edu.au

Further Information

This entry was posted in Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding. Bookmark the permalink.
 

Comments are closed.